** Shares of telehealth firm Hims & Hers Health HIMS.N fall 6.5% to $61.88 premarket
** Trump administration is planning to cover weight-loss drugs under Medicare and Medicaid, Washington Post reports
** Proposed plan would permit state Medicaid programs and Medicare Part D insurance plans to voluntarily cover GLP-1 drugs such as Novo Nordisk's NOVOb.CO Ozempic and Wegovy, as well as Lilly's Mounjaro and Zepbound for weight management, report says
** Proposed plan is expected to start in April 2026 for Medicaid and in January 2027 for Medicare plans, Washington Post reports, citing documents
** As of last close, stock up 173% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。